Literature DB >> 9141418

Histopathologic analysis of transjugular intrahepatic portosystemic shunts.

H Ducoin1, J El-Khoury, H Rousseau, K Barange, J M Peron, M T Pierragi, J L Rumeau, J P Pascal, J P Vinel, F Joffre.   

Abstract

This prospective study was undertaken in 17 patients treated with 22 transjugular intrahepatic portosystemic shunt (TIPS) procedures and aimed to evaluate the nature and causes of short- and long-term shunt abnormalities. Specimens were collected after autopsy in 6 patients and after liver transplantation in 11 patients; the time from shunting ranging from 4 to 385 days. During the first 2 weeks the shunt surface was covered by poorly organized fibrin platelet clots that were mixed with inflammatory and red blood cells. Thereafter, a pseudointima developed, initially made of loose granulation tissue that was formed by edema, myofibroblasts, neo-capillaries, collagen fibers, and inflammatory cells. This pseudo-intima extended with time as the myofibroblasts increased in number, as the collagen fibers thickened, and as the inflammatory cells grew more scarce. Its thickness ranged from 50 to 3,500 microm, the maximal values being observed in the middle of the shunt. The shunt was obstructed by a clot in 4 patients (18%). In 7 shunts (31.8%) the pseudo-intima was thicker than 1,000 microm and was referred to as hyperplastic pseudo-intima. It showed more dense inflammatory infiltrate and anarchic deposition of more scarce collagen fibers. Pseudo-intima hyperplasia was associated with previously diagnosed thrombosis, which had been treated by dilatation in 2 cases and by biliary deposits in 3 cases, while it remained unexplained in 2 cases. Accordingly, this study confirms the following: 1) that early TIPS obstruction results from thrombosis; 2) that 2 weeks after insertion, the stent is covered by a smooth pseudo-intima; 3) that thereafter, pseudo-intimal hyperplasia is the main cause of TIPS stenosis or occlusion; and 4) that biliary secretions and previous thrombosis could be important triggering mechanisms for this pseudo-intima overgrowth.

Entities:  

Mesh:

Year:  1997        PMID: 9141418     DOI: 10.1002/hep.510250503

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Effect of technical parameters on transjugular intrahepatic portosystemic shunts utilizing stent grafts.

Authors:  Brice Andring; Sanjeeva P Kalva; Patrick Sutphin; Rajiv Srinivasa; Alvin Anene; Marc Burrell; Yin Xi; Anil K Pillai
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

2.  Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding.

Authors:  Hui Xue; Meng Zhang; Jack Xq Pang; Fei Yan; Ying-Chao Li; Liang-Shan Lv; Jia Yuan; Muna Palikhe; Wei-Zhi Li; Zhi-Lun Wang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

3.  Covered stents in transjugular portosystemic shunt: healing response to non-porous ePTFE covered stent grafts with and without intraluminal irradiation.

Authors:  Klaus A Hausegger; Horst Portugaller; Nicolas P Macri; Josef Tauss; Peter Schedlbauer; Johannes Deutschmann; Georg Stücklschweiger; Heidi Stranzl
Journal:  Eur Radiol       Date:  2002-10-31       Impact factor: 5.315

4.  Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.

Authors:  Ming Bai; Chuang-Ye He; Xing-Shun Qi; Zhan-Xin Yin; Jian-Hong Wang; Wen-Gang Guo; Jing Niu; Jie-Lai Xia; Zhuo-Li Zhang; Andrew C Larson; Kai-Chun Wu; Dai-Ming Fan; Guo-Hong Han
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

5.  Impact of PTFE-covered stent position and extension on TIPS patency.

Authors:  Joshua K Cho; Juan Serna; Timothy W I Clark; Mandeep Dagli; Jeffrey I Mondschein; Richard D Shlansky-Goldberg; Scott O Trerotola; Michael C Soulen; S William Stavropoulos; Gregory J Nadolski
Journal:  Abdom Radiol (NY)       Date:  2020-11

6.  Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center.

Authors:  Jian-Ping Qin; Ming-De Jiang; Wen Tang; Xiao-Ling Wu; Xin Yao; Wei-Zheng Zeng; Hui Xu; Qian-Wen He; Ming Gu
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

7.  Persistence of gastric or esophageal varices on final angiography increases transjugular intrahepatic portosystemic shunt revision rate after polytetrafluoroethylene-covered stent shunt creation.

Authors:  Benjamin Moulin; Olivier Chevallier; Gilles Abdulmalak; Maxime Luu; Marianne Latournerie; Anne Minello; Sophie Gehin; Jean-Pierre Cercueil; Marco Midulla; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2018-03

8.  The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status.

Authors:  Gilles Pomier-Layrargues; Louis Bouchard; Michel Lafortune; Julien Bissonnette; Dave Guérette; Pierre Perreault
Journal:  Int J Hepatol       Date:  2012-07-19

9.  MRI-monitored intra-shunt local agent delivery of motexafin gadolinium: towards improving long-term patency of TIPS.

Authors:  Han Wang; Feng Zhang; Yanfeng Meng; Tong Zhang; Patrick Willis; Thomas Le; Stephanie Soriano; Erik Ray; Karim Valji; Guixiang Zhang; Xiaoming Yang
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  Effects of intraluminal irradiation with Holmium-166 for TIPS stenosis: experimental study in a swine model.

Authors:  Ji Seon Park; Joo Hyeong Oh; Deog Yoon Kim; Yong Koo Park; Sang Joon Park; Soo Joong Kim
Journal:  Korean J Radiol       Date:  2007 Mar-Apr       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.